Collectively, these studies demonstrated that ANXA3 is highly expressed in luminal A, B and triple negative breast cancer subtypes, and that ANXA3 inhibition could significantly impair tumor growth in vivo, concomitant with a lower proliferation index and a higher apoptosis rate and G0/1 cell count in vitro (Zhou et al., 2017a; Li et al., 2018; Zhou et al., 2018). The gene discussed is ANXA3; the disease is triple-negative breast carcinoma.